這是一項隨機、開放標籤、多中心、全球性第三期研究，旨在評估durvalumab聯合tremelimumab聯合治療及durvalumab單藥治療對比sorafenib在未曾接受全身治療的不可切除HCC患者中的療效與安全性。患者須不符合局部區域治療的條件。
適應症：Hepatocellular Carcinoma
收案條件
納入條件
- HCC based on histopathological confirmation
- No prior systemic therapy for HCC
- Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C
- Child-Pugh Score class A
- ECOG performance status of 0 or 1 at enrollment
排除條件
- Hepatic encephalopathy within past 12 months or requirement for medication to prevent or control encephalopathy
- Clinically meaningful ascites
- Main portal vein tumor thrombosis
- Active or prior documented GI bleeding (eg, esophageal varices or ulcer bleeding) within 12 months
- HBV and HVC co-infection, or HBV and Hep D co-infection
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。